KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Ja 98%
Marktkwaliteit
45 / 100
Lage kwaliteit24u volume
€ 644,8
Liquiditeit
€ 1,9K
Lage liquiditeitBied / Laat
77.0% / 99.0%
Spread
22.0 pt
Brede spreadMarktdata
Bijgewerkt 7 minuten geleden
17 jun 26, 21:00 UTC1 jan 27, 04:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegels
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Afwikkeling via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Open markten
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18,3K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Totaal volume
- € 1,6 mln.
- 24u volume
- € 5,2K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 extra uitkomsten
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Totaal volume
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Totaal volume
- € 916K
- 24u volume
- € 1,5K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 extra uitkomsten
- Totaal volume
- € 863,6K
- 24u volume
- € 1K
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Veelgestelde vragen
- Wat zijn de huidige kansen voor FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi prijst Yes op 98% per 8 september 2026.
- Wanneer wordt FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) afgewikkeld?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) wordt naar verwachting op 1 januari 2027 afgewikkeld.
- Hoe wordt FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.